Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.50 |
| ▸ | PIM1 | P11309 | 2/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 6/20 | 0.48 |
| ▸ | JAK2 | O60674 | 5/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16177033 | 1.00 | USP30 (0.50) | USP30PIM1PIM2TRPV1JAK3 | |
| SCHEMBL16177034 | 1.00 | USP30 (0.50) | USP30PIM1PIM2TRPV1JAK3 | |
| SCHEMBL21598992 | 0.89 | USP30 (0.50) | USP30PIM1PIM2TRPV1JAK3 | |
| SCHEMBL16177328 | 0.88 | POLB (0.50) | USP30PIM1PIM2TRPV1JAK3 | |
| SCHEMBL21598927 | 0.88 | POLB (0.50) | USP30PIM1PIM2TRPV1JAK3 | |
| SCHEMBL31227317 | 0.88 | JAK3 (0.49) | USP30PIM1PIM2TRPV1JAK3 | |
| SCHEMBL16177330 | 0.88 | POLB (0.50) | USP30PIM1PIM2TRPV1JAK3 | |
| SCHEMBL21599059 | 0.88 | USP30 (0.48) | USP30PIM1PIM2TRPV1JAK3 | |
| SCHEMBL31227249 | 0.86 | PIM1 (0.49) | USP30PIM1PIM2TRPV1JAK3 | |
| SCHEMBL31227548 | 0.86 | PIM1 (0.49) | USP30PIM1PIM2TRPV1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | USP30 3093/4885PIM1 709/4885PIM2 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.